ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 154,30
0,66%
DAX
17 896,50
-0,14%
Brent Oil
83,595
0,07%
Bitcoin
59 027,55
1,36%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Virax Biolabs Group Ltd (VRAX)

  7. Virax Biolabs Group Ltd (VRAX) Actualités

VRAX Virax Biolabs Group Ltd

0,649
0,00 (0,00%)
Dernière mise à jour : 19:25:46
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Virax Biolabs Group Ltd VRAX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 0,649 19:25:46
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,66 0,649 0,6681 0,649
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
25/4/202414:00PRNUSVirax Biolabs Launches Portfolio of Immune Profiling..
16/4/202413:30PRNUSVirax Biolabs to Participate at ESCMID Global 2024
15/3/202421:30PRNUSVirax Biolabs Announces Receipt of NASDAQ Notification..
22/1/202423:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/1/202423:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/1/202413:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202313:34EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202313:30PRNUSVirax Biolabs Forges Strategic Research Collaboration with..
20/12/202322:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
20/12/202322:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202322:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/12/202313:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/12/202313:30PRNUSVirax Biolabs' CEO James Foster Issues Letter to..
18/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
14/12/202313:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202313:30PRNUSVirax Biolabs Group Limited Announces 1-for-10 Share..
08/12/202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/202322:06EDGAR2Form F-3 - Registration statement by foreign private issuers
08/11/202322:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202321:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/10/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202313:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202313:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202313:30PRNUSVirax Biolabs Group Announces Early-Access Program Launch of..
01/9/202313:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/9/202313:30PRNUSVirax Biolabs Group Appoints Dr. Nigel McCracken as Chief..
03/8/202314:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/8/202313:30PRNUSNasdaq Approves 180-Day Extension for Virax Biolabs Group to..
18/7/202313:58EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/7/202313:30PRNUSVirax Biolabs Group Continues Growth and Expansion with the..
14/6/202313:30PRNUSVirax Biolabs' CEO James Foster Issues Letter to..
04/5/202313:30PRNUSVirax Biolabs Group Announces Establishment of Regional..

Dernières Valeurs Consultées

NASDAQ
VRAX
Virax Biolabs
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés